Drug interactions of lipid-altering drugs

Drug Safety

Volumn 19, Issue 5, 1998, Pages 355-371

  Bays, Harold E ^a   Dujovne, Carlos A ^b  

^a Landstuhl Regional Medical Center   (United States)

^b Metabolic Diseases Clinics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALCOHOL; ANTIARRHYTHMIC AGENT; ANTIFUNGAL AGENT; ANTILIPEMIC AGENT; COLESTIPOL; COLESTYRAMINE; CYCLOSPORIN; FIBRIC ACID DERIVATIVE; FUROSEMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MACROLIDE; NICOTINIC ACID; ORAL ANTIDIABETIC AGENT; PHENOTHIAZINE DERIVATIVE; PROBENECID; PROBUCOL; PYRROLE; TRICYCLIC ANTIDEPRESSANT AGENT; URICOSURIC AGENT; WARFARIN;

ATHEROSCLEROSIS; DISEASE COURSE; DRUG ABSORPTION; HEART INFARCTION; HUMAN; LIVER TOXICITY; MYOSITIS; PRIORITY JOURNAL; REVIEW; STROKE;

ANTILIPEMIC AGENTS; DRUG INTERACTIONS; FISH OILS; GEMFIBROZIL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NIACIN; PROBUCOL; PROCETOFEN; RESINS, PLANT;

EID: 0031761558     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199819050-00003     Document Type: Review

References (57)

1. Pentikainen PJ, Saraheimo M, Schwartz JI, et al. Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans. J Clin Pharmacol 1992; 32 (2): 136-40
2. Garnett WR. Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am J Health Syst Pharm 1995; 52: 1639-45
3. Lipitor (atorvastatin calcium). Package insert. Morris Plains (NJ): Warner-Lambert Co., January 1997
4. Meyer UA. Overview of enzymes of drug metabolism. J Pharmacokinet Biopharm 1996; 24 (5): 449-59
5. Darlene NJ. Letter in reply. JAMA 1997; 277: 296-7
6. Singer MI, Shapiro LE, Shear NH. Cytochrome P-450 3A: interactions with dermatologic therapies. J Am Acad Dermatol 1997; 37: 765-72
7. Katz HI, Gupta AK. Oral antifungal drug interactions. Dermatol Clin 1997; 15: 535-8
8. Suga V, MedWatch News - urgent recall. Nutley (NJ): Public Affairs Department, Hoffmann-LaRoche Inc., 1998
9. Jacobson RH, Wang P, Glueck CJ, Jody GN. Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone [letter]. JAMA 1997; 277: 296
10. Grunden J, Fisher K. Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin. Ann Pharmacother 1997; 31: 859-63
11. Bays HE, Dujovne DA. Drugs for treatment of patients with high cholesterol blood levels and other dyslipidemias. Progress in Drug Research 1994; 43: 9-41
12. Pravachol (pravastatin sodium). Package insert. Princeton (NJ): Bristol-Meyers Squibb Company, May 1998
13. Mevacor (lovastatin). Package Insert. West Point (PA): Merck and Co., March 1997
14. Baycol (cerivastatin sodium). Package insert. West Haven (CT): Bayer Corporation, 1997
15. Physicians Desk Reference. 52nd ed. Montvale (NJ): Medical Economics, 1998: 1862-5
16. Zocor (simvastatin). Package insert. West Point (PA): Merck and Co., July 1998
17. Pan HY, Triscari J, DeVault AR, et al. Pharmacokinetic interaction between propranolol and the HMG-CoA reductase inhibitors pravastatin and lovastatin. Br J Clin Pharmacol 1991; 31 (6): 665-70
18. Posicor (mibefradil dihydrochloride). Package insert. Nutley (NJ): Roche, December 1997
19. Nakai A, Nishikata M, Matsuyama K, et al. Drug interaction between simvastatin and cholestyramine in vitro and in vivo. Biol Pharm Bull 1996; 19 (9): 1231-3
20. Davignon J, Roederer G, Montigny M. Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia. Am J Cardiol 1994; 73: 339-45
21. Pasternak RC, Brown LE, Stone PH. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and 'normal' cholesterol levels. Ann Intern Med 1996; 125: 529-40
22. Stein EA, Davidson MH, Dujovne CA, et al. Efficacy and tolerability of low-dose simvastatin and niacin, alone and in combination, in patients with combined hyperlipidemia: a prospective trial. J Cardiovasc Pharmacol Ther 1996; 1 (2): 107-16
23. Jacobson TA. Fluvastatin with and without niacin for hypercholesterolemia. Am J Cardiol 1994; 74 (2): 149-54
24. Stein EA, Davidson MH, Dobs AS, et al. Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients. Am J Cardiol 1998; 82: 311-6
25. Tobert JA, Shear CL, Chremos AN, et al. Clinical experience with lovastatin. Am J Cardiol 1990; 65 (12): 23F-26F
26. Ahmad-S. Lovastatin-warfarin interaction [letter]. Arch Intern Med 1990; 150 (11): 2407
27. Gaw A, Wosornu D. Simvastatin during warfarin therapy in hyperlipoproteinaemia [letter] Lancet 1992; 340 (8825): 979-80
28. Grau E, Perella M, Pastor E. Simvastatin-oral anticoagulant interaction [letter]. Lancet 1996; 347 (8998): 405-6
29. Trilli LE, Kelley CL, Aspinall SL, et al. Potential interaction between warfarin and fluvastatin. Ann Pharmacother 1996; 30 (12): 1399-402
30. Jungnickel PW, Cantral KA, Maloley PA. Pravastatin: a new drug for the treatment of hypercholesterolemia. Clin Pharm 1992: 11 (8): 677-89
31. Stern R, Abel R, Gibson GL, et al. Atorvastatin does not alter the anticoagulant activity of warfarin. J Clin Pharmacol 1997; 37 (11): 1062-4
32. Olbricht C, Wanner C, Eisenbauer T, et al. Accumulation of lovastatin, but not pravastatin in the blood of cyclosporin-treated kidney graft patients after multiple doses. Clin Pharmacol Ther 1997; 62: 311-21
33. Christians U. Combination of pravastatin and cyclosporin in transplant patients. Clin Pharmacokinet 1997; 32: 173-4
34. Wiklund O, Bergman M, Bondjers G, et al. Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am J Med 1993; 94: 13-9
35. Goldberg R, Roth D. Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant patients taking cyclosporine. Transplantation 1996; 62 (11): 1559-64
36. Garnett WR, Venitz J, Wilkens RC, et al. Pharmacokinetic effects of fluvastatin in patients chronically receiving digoxin. Am J Med 1994; 96 Suppl. 6A: 84S-86S
37. Aberg J, Eriksson U, Fager G. Effects of erthyromycin on plasma fluvastatin levels: a pharmacokinetic study [abstract]. 11th International Symposium on Atherosclerosis: 1997 Oct; Paris
38. Spence JD, Munoz CE, Hendricks L. Pharmacokinetics of the combination of fluvastatin and gemfibrozil. Am J Cardiol 1995; 76: 80-3
39. Physicians Desk Reference. 2nd ed. Montvale (NJ): Medical Economics, 1998: 2253
40. Physicians Desk Reference. 52nd ed. Montvale (NJ): Medical Economics, 1998: 812
41. Farmer JA, Jr Gotto AM. Antihyperlipidemic agents: drug interactions of clinical significance. Drug Saf 1994; 11: 301-9
42. Lozada A, Dujovne CA. Drug interactions with fibric acids. Pharmacol Ther 1994; 63: 163-76
43. Daubresse JC, Luyckx AS, Lefebvre PJ. Potentiation of hypoglycemic effect of sulfonylureas by clofibrate [letter]. N Engl J Med 1976; 294 (11): 613
44. Daubresse JC, Daigneux D, Bruwier M, et al. Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents. Br J Clin Pharmacol 1979; 7 (6): 599-603
45. O'Reilly RA, Sahud MA, Robinson AJ. Studies on the interaction of warfarin and clofibrate in man. Thromb Diath Haemorrh 1972; 27 (2): 309-18
46. Fehrman-Ekholm I, Jogestrand T, Angelin B. Decreased cyclosporin levels during gemfibrozil treatment of hyperlipidemia after kidney transplantation [letter]. Nephron 1996; 72: 483
47. Illingworth DR, Bacon S. Influence of lovastatin plus gemfibrozil on plasma lipids and lipoproteins in patients with heterozygous familial hypercholesterolemia. Circulation 1989; 79 (3): 590-6
48. Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990; 264 (1): 71-5
49. Marais GE, Larson KK. Rhabdomyolysis and acute renal failure induced by combination lovastatin and gemfibrozil therapy. Ann Intern Med 1990; 112 (3): 228-30
50. Rosenson RS. Gemfibrozil-lovastatin-associated myalgia [letter]. Am J Cardiol 1993; 71 (5): 497
51. Ding RW, Kolbe K, Merz B, et al. Pharmacokinetics of nicotinic acid-salicylic acid interaction. Clin Pharmacol Ther 1989; 46 (6): 642-7
52. Jr Rockwell KA. Potential interactions between niacin and transdermal nicotine. Ann Pharmacother 1993; 27: 1283-4
53. Norman DJ, Illingworth DR, Munson J, et al. Myolysis and acute renal failure in a heart-transplant recipient receiving lovastalin [letter]. N Engl J Med 1988; 318 (1): 46-7
54. Reaven P, Witztum JL, Lovastatin, nicotinic acid, and rhabdomyolysis [letter]. Ann Intern Med 1988; 109 (7): 597-8
55. Zucker ML, Trowbridge C, Woodroof J, et al. High dose aspirin: effects on platelet function in hyperlipoproteinemic and normal subjects. Arch Intern Med 1986; 146: 921-5
56. Mueller BA, Talbert RL, Tegeler CH. The bleeding time effects of a single dose of aspirin in subjects receiving omega-3-fatty acid dietary supplementation. J Clin Pharmacol 1991; 31: 185-90
57. Dujovne CA, Harris WS, Gerrond LL, et al. Comparison of effects of probucol versus vitamin E on ex vivo oxidation susceptibility of lipoproteins in hyperlipoproteinemia. Am J Cardiol 1994; 74: 38-42